Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $193,733.60 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,840 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $105.29, for a total value of $193,733.60. Following the completion of the sale, the senior vice president directly owned 1,274 shares in the company, valued at approximately $134,139.46. This represents a 59.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total value of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $100.65 on Friday. Mirum Pharmaceuticals, Inc. has a 1 year low of $57.79 and a 1 year high of $130.00. The firm’s 50-day moving average is $110.33 and its 200 day moving average is $101.79. The stock has a market cap of $6.14 billion, a price-to-earnings ratio of -6.92 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 1.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) earnings per share. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MIRM. TD Cowen decreased their price objective on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a report on Thursday. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday. Wall Street Zen raised Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright decreased their price target on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Morgan Stanley set a $137.00 price target on Mirum Pharmaceuticals in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $137.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. bought a new stake in Mirum Pharmaceuticals in the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $32,000. CIBC Private Wealth Group LLC bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. State of Wyoming bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at $52,000. Finally, Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth $33,000.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.